Roivant Sciences (NASDAQ:ROIV) Director Melissa Epperly Sells 41,861 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Melissa Epperly sold 41,861 shares of Roivant Sciences stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the sale, the director owned 15,804 shares in the company, valued at approximately $453,258.72. This represents a 72.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Roivant Sciences Trading Down 1.8%

ROIV stock traded down $0.50 during trading on Wednesday, hitting $27.80. The company had a trading volume of 4,345,944 shares, compared to its average volume of 6,400,057. The business has a 50 day moving average of $25.57 and a 200 day moving average of $20.99. The firm has a market capitalization of $19.90 billion, a price-to-earnings ratio of -23.76 and a beta of 1.17. Roivant Sciences Ltd. has a fifty-two week low of $8.73 and a fifty-two week high of $30.33.

Analyst Ratings Changes

Several research firms have recently issued reports on ROIV. Jefferies Financial Group reiterated a “buy” rating on shares of Roivant Sciences in a report on Tuesday, March 3rd. Weiss Ratings cut Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, February 9th. HC Wainwright upped their target price on Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Finally, Guggenheim lifted their price target on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $28.81.

Hedge Funds Weigh In On Roivant Sciences

Several hedge funds have recently made changes to their positions in ROIV. UBS Group AG boosted its holdings in Roivant Sciences by 570.0% during the fourth quarter. UBS Group AG now owns 18,390,792 shares of the company’s stock worth $399,080,000 after buying an additional 15,645,836 shares in the last quarter. Morgan Stanley increased its holdings in shares of Roivant Sciences by 31.7% in the fourth quarter. Morgan Stanley now owns 58,359,553 shares of the company’s stock valued at $1,266,402,000 after buying an additional 14,036,696 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Roivant Sciences by 365.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock valued at $238,323,000 after buying an additional 8,621,567 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Roivant Sciences by 11,507.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 6,937,112 shares of the company’s stock valued at $150,535,000 after acquiring an additional 6,877,348 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Roivant Sciences during the 4th quarter valued at $112,750,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.